Clinical Trial Detail

NCT ID NCT01530984
Title Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
Recruitment Withdrawn
Gender male
Phase Phase II
Variant Requirements No
Sponsors Lawrence Fong
Indications

prostate cancer

Therapies

Sargramostim

Ipilimumab

Age Groups: adult

No variant requirements are available.